ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Rutin attenuates Tramadol-induced lung injury in rats by modulating oxidative stress, inflammation, endoplasmic reticulum stress, and apoptosis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tramadol (TRM) is a commonly prescribed opioid analgesic; however, accumulating evidence suggests that it may exert toxic effects on vital organs, including the lungs. This study aimed to elucidate the mechanisms underlying TRM-induced lung injury and to investigate the potential protective role of rutin (RUT), a bioactive flavonoid with potent antioxidant and anti-inflammatory properties. In a rat model, lung tissues were analyzed using histopathological examination, biochemical assays for oxidative stress parameters, RT-qPCR for gene expression analysis [nuclear factor E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNF-α), inducible nitric oxide synthase (iNOS), Bax, Bcl-2, and Caspase-3], and immunohistochemical (IHC) evaluation of Beclin-1 and 3-nitrotyrosine (3-NT) expression. TRM administration caused severe pulmonary structural alterations, including alveolar collapse, interalveolar septal thickening, inflammatory infiltration, edema, and hemorrhage. These histopathological changes were associated with pronounced oxidative stress, as evidenced by suppressed superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities, depletion of glutathione (GSH), increased lipid peroxidation, and disruption of the Nrf2/HO-1/NQO1 antioxidant signaling axis. Furthermore, TRM markedly activated endoplasmic reticulum (ER) stress responses (PERK and ATF-6), upregulated apoptotic markers (Bax and Caspase-3), downregulated Bcl-2 expression, and enhanced autophagy-related Beclin-1 immunoreactivity. In parallel, significant activation of inflammatory and nitrosative pathways was observed, characterized by elevated NF-κB, TNF-α, and iNOS expression and increased nitrotyrosine accumulation. In contrast, RUT treatment substantially ameliorated TRM-induced lung injury by restoring antioxidant capacity, suppressing ER stress-mediated apoptosis and autophagy, and attenuating inflammatory and nitrosative responses. Overall, these findings demonstrate that RUT confers significant protection against TRM-induced pulmonary toxicity through coordinated modulation of oxidative stress, ER stress, apoptosis, autophagy, and inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.